Half of 22 patients in a Phase 1 trial achieving composite complete remission is not the number that defines Senti Biosciences’ current strategic position — it’s the fraction of donors who carry a specific biological attribute that does. The company has identified what it calls a “Donor X” characteristic present in roughly 50% of adult donors, independent of HLA or KIR matching, that correlates sharply with SENTI-202’s efficacy: 7 of 14 patients who received cells manufactured from Donor X-derived NK cells in Cycle 1 hit composite CR. That discovery restructures the entire manufacturing thesis for an allogeneic off-the-shelf CAR-NK program, because it converts a vague potency variable into a selectable input — every future batch will be sourced from Donor X-positive material.
The FDA endorsed a single-arm, multi-center pivotal trial design for R/R AML following a Type B RMAT meeting, which is not a trivial outcome. Single-arm registration paths in AML are rare and depend entirely on the agency accepting composite CR as a credible surrogate endpoint. That Senti secured this clarity with an RMAT designation in hand, before spending pivotal capital, is the most operationally valuable thing that happened this quarter — more so than the $10 million initial tranche of convertible notes from Celadon Partners, which offers up to $40 million total but loads the balance sheet with senior secured debt and contingent value rights tied to milestones Senti has not yet hit.
The financial picture is precarious but not irrational for the stage. Cash burned at $7.5 million in Q1 2026 against $8.9 million remaining as of March 31 — meaning the company entered pivotal planning essentially dependent on that Celadon tranche closing in May. R&D spend dropped 43% year-over-year to $5.3 million, partly through genuine restructuring and partly through the Alameda facility sublease that generated a one-time $6.9 million accounting gain. Strip that out and the net loss picture looks considerably worse. The company is running lean by necessity, not design.
The single number to watch is the composite CR rate in the pivotal cohort once enrollment opens — specifically whether the Donor X manufacturing lock holds that 50% response rate at scale, because the entire registration strategy collapses if that signal was an artifact of a 14-patient subset.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
